In vitro stability and permeability studies of liposomal delivery systems for a novel lipophilic endomorphin 1 analogue

International Journal of Pharmaceutics

Volumn 356, Issue 1-2, 2008, Pages 37-43

  Koda, Yasuko ^a   Liang, Ming Tao ^a   Blanchfield, Joanne T ^a   Toth, Istvan ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Drug delivery; Endomorphin; Lipopeptide; Liposomes; Opioid peptide delivery

Indexed keywords

2 AMINODODECANOIC ACID; ENDOMORPHIN 1; LIPOPEPTIDE; LIPOSOME; PHOSPHATIDYLCHOLINE;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG PENETRATION; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENCAPSULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIPOPHILICITY; PRIORITY JOURNAL;

ANALGESICS, OPIOID; BIOLOGICAL AVAILABILITY; CACO-2 CELLS; DRUG DELIVERY SYSTEMS; DRUG STABILITY; HUMANS; HYDROPHOBICITY; LIPOSOMES; OLIGOPEPTIDES; PERMEABILITY; PHOSPHATIDYLCHOLINES; SOLUBILITY;

EID: 42649132468     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2007.12.036     Document Type: Article

References (35)

1. Abbadie C., Rossi G.C., Orciuolo A., Zadina J.E., and Pasternak G.W. Anatomical and functional correlation of the endomorphins with μ-opioid receptor splice variants. Eur. J. Neurosci. 16 (2002) 1075-1082
2. Adessi C., and Soto C. Converting a peptide into a drug: strategies to improve stability and bioavailability. Curr. Med. Chem. 9 (2002) 963-978
3. Alewood P., Alewood D., Miranda L., Love S., Meutermans W., and Wilson D. Rapid in situ neutralization protocols for Boc and Fmoc solid-phase chemistries. Methods Enzymol. 289 (1997) 14-29
4. Artursson P., and Karlsson J. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem. Biophys. Res. Commun. 175 (1991) 880-885
5. Artursson P., Palm K., and Luthman K. Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv. Drug Deliv. Rev. 46 (2001) 27-43
6. Blanchfield J., and Toth I. Lipid, sugar and liposaccharide based delivery systems 2. Curr. Med. Chem. 11 (2004) 2375-2382
7. Blanchfield J.T., Dutton J.L., Hogg R.C., Gallagher O.P., Craik D.J., Jones A., Adams D.J., Lewis R.J., Alewood P.F., and Toth I. Synthesis, structure elucidation, in vitro biological activity, toxicity, and Caco-2 cell permeability of lipophilic analogues of alpha-conotoxin MII. J. Med. Chem. 46 (2003) 1266-1272
8. Chhabra S.R., Hothi B., Evans D.J., White P.D., Bycroft B.W., and Chan W.C. An appraisal of new variants of Dde amine protecting group for solid phase peptide synthesis. Tetrahedron Lett. 39 (1998) 1603-1606
9. Csullog E., Joo G., Toth G., Dobos D., Benedek G., and Horvath G. Antinociceptive effect of continuous intrathecal administration of endomorphin-1. Pain 94 (2001) 31-38
10. Degim Z., Unal N., Essiz D., and Abbasoglu U. The effect of various liposome formulations on insulin penetration across Caco-2 cell monolayer. Life Sci. 75 (2004) 2819-2827
11. Fahr A., van Hoogevest P., May S., Bergstrand N., and Leigh M.L.S. Transfer of lipophilic drugs between liposomal membranes and biological interfaces: consequences for drug delivery. Eur. J. Pharm. Sci. 26 (2005) 251-265
12. Flinn N., Coppard S., and Toth I. Oral absorption studies of lipidic conjugates of thyrotropin releasing hormone (TRH) and luteinizing hormone-releasing hormone (LHRH). Int. J. Pharm. 137 (1996) 33-39
13. Forssen E., and Willis M. Ligand-targeted liposomes. Adv. Drug Deliv. Rev. 29 (1998) 249-271
14. Gibbons W.A., Hughes R.A., Charalambous M., Christodoulou M., Szeto A., Aulabaugh A.E., Mascagni P., and Toth I. Lipidic peptides 1: synthesis, resolution and structural elucidation of lipidic amino acids and their homo oligomers and heterooligomers. Liebigs Ann. Chem. (1990) 1175-1183
15. Goldberg I.E., Rossi G.C., Letchworth S.R., Mathis J.P., Ryan-Moro J., Leventhal L., Su W., Emmel D., Bolan E.A., and Pasternak G.W. Pharmacological characterization of endomorphin-1 and endomorphin-2 in mouse brain. J. Pharmacol. Exp. Ther. 286 (1998) 1007-1013
16. Gutman R.L., Peacock G., and Lu D.R. Targeted drug delivery for brain cancer treatment. J. Controll. Release 65 (2000) 31-41
17. Hackler L., Zadina J.E., Ge L.J., and Kastin A.J. Isolation of relatively large amounts of endomorphin-1 and endomorphin-2 from human brain cortex. Peptides 18 (1997) 1635-1639
18. Hidalgo I.J., and Li J.B. Carrier mediated transport and efflux mechanisms in Caco-2 cells. Adv. Drug Deliv. Rev. 22 (1996) 53-66
19. 2+ channel currents in rodent NG108-15 cells overexpressing μ-opioid receptors. J. Physiol. (Lond.) 507 (1998) 71-75
20. Howell S., Brewis I.A., Hooper N.M., Kenny A.J., and Turner A.J. Mosaic expression of membrane peptidases by confluent cultures of Caco-2 cells. FEBS Lett. 317 (1993) 109-112
21. Howell S., Kenny A.J., and Turner A.J. A survey of membrane peptidases in two human colonic cell lines, Caco-2 and HT-29. Biochem. J. 284 (1992) 595-601
22. Iwanaga K., Ono S., Narioka K., Kakemi M., Morimoto K., Yamashita S., Namba Y., and Oku N. Application of surface coated liposomes for oral delivery of peptide: effects of coating the liposome's surface on the GI transit of insulin. J. Pharm. Sci. 88 (1999) 248-252
23. Kastin A.J., Pan W.H., Maness L.M., and Banks W.A. Peptides crossing the blood-brain barrier: some unusual observations. Brain Res. 848 (1999) 96-100
24. Koda, Y., Del Borgo, M., Lazarus, L.H., Okada, Y., Toth, I., Blanchfield, J.T., Jan. 2008. Synthesis and in vitro evaluation of a library of modified Endomorphin 1 peptides. Bioorg. Med. Chem., submitted for publication
25. Liang M.T., Davies N.M., and Toth I. Encapsulation of lipopeptides within liposomes: effect of number of lipid chains, chain length and method of liposome preparation. Int. J. Pharm. 301 (2005) 247-254
26. Martin-Schild S., Gerall A.A., Kastin A.J., and Zadina J.E. Differential distribution of endomorphin 1 and endomorphin 2-like immunoreactivities in the CNS of the rodent. J. Comp. Neurol. 405 (1999) 450-471
27. Pauletti G.M., Gangwar S., Siahaan T.J., Aube J., and Borchardt R.T. Improvement of oral peptide bioavailability: peptidomimetics and prodrug strategies. Adv. Drug Deliv. Rev. 27 (1997) 235-256
28. Rousselle C., Clair P., Smirnova M., Kolesnikov Y., Pasternak G.W., Gac-Breton S., Rees A.R., Scherrmann J.M., and Temsamani J. Improved brain uptake and pharmacological activity of dalargin using a peptide-vector-mediated strategy. J. Pharmacol. Exp. Ther. 306 (2003) 371-376
29. Stone L.S., Fairbanks C.A., Laughlin T.M., Nguyen H.O., Bushy T.M., Wessendorf M.W., and Wilcox G.L. Spinal analgesic actions of the new endogenous opioid peptides endomorphin-1 and -2. Neuroreport 8 (1997) 3131-3135
30. + that release and protect the native hormones in homogenates of human intestinal epithelial (Caco-2) cells. Int. J. Pharm. 105 (1994) 241-247
31. Wenk M.R., Fahr A., Reszka R., and Seelig J. Paclitaxel partitioning into lipid bilayers. J. Pharm. Sci. 85 (1996) 228-231
32. Witt K.A., Huber J.D., Egleton R.D., Roberts M.J., Bentley M.D., Guo L.H., Wei H.B., Yamamura H.I., and Davis T.P. Pharmacodynamic and pharmacokinetic characterization of poly(ethylene glycol) conjugation to met-enkephalin analog [d-Pen(2), d-Pen(5)]-enkephalin (DPDPE). J. Pharmacol. Exp. Ther. 298 (2001) 848-856
33. Zadina J.E., Hackler L., Ge L.-J., and Kastin A. Potent and selective endogenous agonist the μ-opioid receptor. Nature 386 (1997) 499-502
34. Zhang X.C., Jackson J.K., and Burt H.M. Determination of surfactant critical micelle concentration by a novel fluorescence depolarization technique. J. Biochem. Biophys. Methods 31 (1996) 145-150
35. Zornoza T., Cano-Cebrian M.J., Nalda-Molina R., Guerri C., Granero L., and Polache A. Assessment and modulation of acamprosate intestinal absorption: comparative studies using in situ, in vitro (Caco-2 cell monolayers) and in vivo models. Eur. J. Pharm. Sci. 22 (2004) 347-356